FLNA

Filana Therapeutics, Inc.
CAPPED RATING

Filana Therapeutics, Inc. (FLNA) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B+
Factor Score 3.6 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA 1.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -49.5%
Price Return 12M -84.2%
Catalyst Signal 0.00
Market Cap $24.2M
TTM Revenue N/A
Price / Sales N/A
ROE -60.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B+ (3.6) D+ (1.8) C- (1.9) D (1.2) C+ (2.6) C (2.2)
2026-11-05 B+ (3.6) D+ (1.8) B- (2.9) D (1.4) C+ (2.7) C (2.5)
2026-10-29 B (3.5) D+ (1.8) B- (2.9) D (1.4) C+ (2.7) C (2.5)
2026-10-22 B (3.5) C- (1.9) B- (2.9) D (1.5) C+ (2.6) C (2.5)
2026-10-15 B+ (3.5) D+ (1.8) B- (2.9) D (1.3) C+ (2.6) C (2.4)
Page 1 of 4